Cited by 4,110Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 116 of the 119 references it cites were found in a registry or an index.

Epidemiology of Parkinson's disease

de Lau, Lonneke ML, Breteler, Monique MB·2006·The Lancet Neurology

DOI 10.1016/s1474-4422(06)70471-9

Open this paper in CoChat — free account

Abstract

The causes of Parkinson's disease (PD), the second most common neurodegenerative disorder, are still largely unknown. Current thinking is that major gene mutations cause only a small proportion of all cases and that in most cases, non-genetic factors play a part, probably in interaction with susceptibility genes. Numerous epidemiological studies have been done to identify such non-genetic risk factors, but most were small and methodologically limited. Larger, well-designed prospective cohort studies have only recently reached a stage at which they have enough incident patients and person-years of follow-up to investigate possible risk factors and their interactions. In this article, we review what is known about the prevalence, incidence, risk factors, and prognosis of PD from epidemiological studies.

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(06)70471-9

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,777
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Eeden, S. K. V. D. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,805
Prevalence and Characteristics of Dementia in Parkinson Disease
Aarsland, D., Andersen, K., Larsen, J. O., & Lolk, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.3.387 · Cited by 1,403
Alzheimer's Disease and Parkinson's Disease
Nussbaum, R. L., & Ellis, C. E. (2003) · New England Journal of Medicine · doi:10.1056/nejm2003ra020003 · Cited by 1,351
SIC Task Force appraisal of clinical diagnostic criteria for parkinsonian disorders
Litvan, I., Bhatia, K. P., Burn, D. J., Goetz, C. G., Lang, A. E., McKeith, I. G., Quinn, N. P., Sethi, K. D., Shults, C. W., & Wenning, G. K. (2003) · Movement Disorders · doi:10.1002/mds.10459 · Cited by 1,011
Parkinson Disease in Twins
Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 876
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD)
Defer, G., Widner, H., Mari�, R.-M., Rémy, P., & Levivier, M. (1999) · Movement Disorders · doi:10.1002/1531-8257(199907)14:4 · Cited by 863
The incidence and lifetime prevalence of neurological disorders in a prospective community-based study in the UK
MacDonald, B. K. (2000) · Brain · doi:10.1093/brain/123.4.665 · Cited by 858

Show all 119 references

Research works printed but not linked: 3

Fink, 2001, Caffeine intake and the risk of incident Parkinson's disease: the Framingham Study, Mov Disord, 16, 984
Anderson, 1999, Dietary factors in Parkinson's disease: the role of food groups and specific foods, Mov Disord, 14, 21, 10.1002/1531-8257(199901)14:1<21::AID-MDS1006>3.0.CO;2-Y · DOI
De Lau LM, Koudstaal PJ, Witteman J, Hofman A, Breteler MM. Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease. Neurology (in press).

Sorted by citations

Items 901–1,000 of 1,019

Cell-Replacement and Gene-Therapy Strategies for Parkinson‘s and Alzheimer‘s Disease
Korecka, J. A., Verhaagen, J., & Hol, E. M. (2007) · Regenerative Medicine · doi:10.2217/17460751.2.4.425 · Cited by 48
“m en de d [4 9]”
Background
The Role of Oxygen Homeostasis and the HIF-1 Factor in the Development of Neurodegeneration
Mitroshina, E. V., & Vedunova, M. V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25094581 · Cited by 48
Statistical theories of functions and the problem of epidemic disease
Kraemer, D. M. (2013) · Biology & Philosophy · doi:10.1007/s10539-013-9365-3 · Cited by 48
“7 Source: de Lau and Breteler (2006). 432 D.”
Background
Voice characteristics from isolated rapid eye movement sleep behavior disorder to early Parkinson's disease
Jeancolas, L., Mangone, G., Petrovska‐Delacrétaz, D., Benali, H., Benkelfat, B.-E., Arnulf, I., Corvol, J., Vidailhet, M., & Lehéricy, S. (2022) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2022.01.003 · Cited by 48
Rhythmic auditory stimulation promotes gait recovery in Parkinson's patients: A systematic review and meta-analysis
Ye, X., Li, L., He, R. X., Jia, Y., & Poon, W. S. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.940419 · Cited by 48
Sphingolipids in neurodegenerative diseases
Pan, X., Dutta, D., Lu, S., & Bellen, H. J. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1137893 · Cited by 50
C1q and central nervous system disorders
Zhang, W., Chen, Y., & Pei, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1145649 · Cited by 49
Contribution of different handwriting modalities to differential diagnosis of Parkinson's Disease
Drotár, P., Mekyska, J., Smékal, Z., Rektorová, I., Masárová, L., & Faúndez-Zanuy, M. (2015) · IEEE International Symposium on Medical Measurements and Applications (MeMeA) · doi:10.1109/memea.2015.7145225 · Cited by 48
Automatic Trajectory Planning of DBS Neurosurgery from Multi-modal MRI Datasets
Bériault, S., Subaie, F. A., Mok, K., Sadikot, A. F., & Pike, G. B. (2011) · Lecture notes in computer science · doi:10.1007/978-3-642-23623-5_33 · Cited by 48
Use of a Refined Drug Tracer Algorithm to Estimate Prevalence and Incidence of Parkinson's Disease in a Large Israeli Population
Chillag-Talmor, O., Giladi, N., Linn, S., Gurevich, T., El‐Ad, B., SILVERMAN, B. G., Friedman, N. L., & Peretz, C. (2011) · Journal of Parkinson s Disease · doi:10.3233/jpd-2011-11024 · Cited by 52
“For UK, Sweden, Italy, Spain, USA and other developed countries, rate ranges were: 60–350/100,000 for prevalence, 5–26/100,000 for incidence [4–7, 23].”
BackgroundInfluential
Risk of developing P arkinson's disease among patients with asthma: a nationwide longitudinal study
Cheng, C. ‐., Wu, Y. ‐., Tsai, S., Bai, Y. ‐., Hsu, J.-W., Huang, K., Su, T. ‐., Li, C., Tsai, C. ‐., Yang, A. C., et al. (2015) · Allergy · doi:10.1111/all.12758 · Cited by 48
Reduced Risk of Parkinson’s Disease in Users of Calcium Channel Blockers: A Meta-Analysis
Gudala, K., Kanukula, R., & Bansal, D. (2015) · International Journal of Chronic Diseases · doi:10.1155/2015/697404 · Cited by 48
A mutation in Drosophila methuselah resists paraquat induced Parkinson-like phenotypes
Shukla, A. K., Pragya, P., Chaouhan, H. S., Patel, D. K., Abdin, M. Z., & Chowdhuri, D. K. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.008 · Cited by 48
Subthalamic deep brain stimulation improves smooth pursuit and saccade performance in patients with Parkinson’s disease
Nilsson, M. H., Patel, M., Rehncrona, S., Magnusson, M., & Fransson, P.-A. (2013) · Journal of NeuroEngineering and Rehabilitation · doi:10.1186/1743-0003-10-33 · Cited by 48
Epigenetic Basis of Neuronal and Synaptic Plasticity
Karpova, N. N., Sales, A. J., & Joca, S. R. L. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160414124628 · Cited by 51
A Search for SNCA 3′ UTR Variants Identified SNP rs356165 as a Determinant of Disease Risk and Onset Age in Parkinson’s Disease
Cardo, L. F., Coto, E., de Mena, L., Ribacoba, R., Lorenzo‐Betancor, O., Pástor, P., Samaranch, L., Mata, I. F., Díaz, M., Morís, G., et al. (2011) · Journal of Molecular Neuroscience · doi:10.1007/s12031-011-9669-1 · Cited by 49
DJ ‐1 modulates mitochondrial response to oxidative stress: clues from a novel diagnosis of PARK7
Nottia, M. D., Masciullo, M., Verrigni, D., Petrillo, S., Modoni, A., Rizzo, V., Giuda, D. D., Rizza, T., Niceta, M., Torraco, A., et al. (2016) · Clinical Genetics · doi:10.1111/cge.12841 · Cited by 48
Utility and implications of exome sequencing in early‐onset Parkinson's disease
Trinh, J., Lohmann, K., Baumann, H., Balck, A., Borsche, M., Brüggemann, N., Dure, L. S., Dean, M. N., Volkmann, J., Tunç, S., et al. (2018) · Movement Disorders · doi:10.1002/mds.27559 · Cited by 48
A Systematic Review of the Neurocognitive Effects of Cannabis Use in Older Adults
Scott, E. P., Brennan, E., & Benitez, A. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00285-9 · Cited by 48
GDNF-expressing macrophages restore motor functions at a severe late-stage, and produce long-term neuroprotective effects at an early-stage of Parkinson’s disease in transgenic Parkin Q311X(A) mice
Zhao, Y., Haney, M. J., Jin, Y. S., Uvarov, O., Vinod, N., Lee, Y. Z., Langworthy, B., Fine, J. P., Rodriguez, M., El‐Hage, N., et al. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.027 · Cited by 46
The Effect of Virtual Reality on the Ability to Perform Activities of Daily Living, Balance During Gait, and Motor Function in Parkinson Disease Patients
Chen, L., Guoen, C., Huidan, W., Yingqing, W., Chen, Y., Xiao-chun, C., & Ye, Q. (2020) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0000000000001447 · Cited by 48
Actively targeted gold nanoparticle composites improve behavior and cognitive impairment in Parkinson's disease mice
Liu, L., Li, M., Xu, M., Wang, Z., Zeng, Z., Li, Y.-Q., Zhang, Y., You, R., Li, C., & Guan, Y. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111028 · Cited by 49
Autophagy-dependent removal of α-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson’s disease
Guo, Y., Duan, W., Lu, D.-H., Ma, X., Li, X., Zhao, L., Bi, W., Kurihara, H., Liu, H., Li, Y., et al. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-0454-y · Cited by 49
Istradefylline to Treat Patients with Parkinson’s Disease Experiencing “Off” Episodes: A Comprehensive Review
Berger, A. A., Winnick, A. A., Welschmeyer, A. F., Kaneb, A., Berardino, K., Cornett, E. M., Kaye, A. D., Viswanath, O., & Urits, I. (2020) · Neurology International · doi:10.3390/neurolint12030017 · Cited by 48
“The diagnosis of PD is largely a clinical one, though imaging studies can be supportive [1].”
BackgroundInfluential
Zonisamide for the Treatment of Parkinson Disease: A Current Update
Li, C., Li, X., Liu, Y., Yang, Z., Chi, S., & Xie, A. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.574652 · Cited by 48
High-throughput behavioral screen in C. elegans reveals Parkinson’s disease drug candidates
Sohrabi, S., Mor, D. E., Kaletsky, R. L., Keyes, W. D., & Murphy, C. T. (2021) · Communications Biology · doi:10.1038/s42003-021-01731-z · Cited by 48
Early-Onset Parkinsonism and Early-Onset Parkinson’s Disease: A Population-Based Study (2010-2015)
Camerucci, E., Stang, C. D., Hajeb, M., Turcano, P., Mullan, A. F., Martin, P., Ross, O. A., Bower, J. H., Mielke, M. M., & Savica, R. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202464 · Cited by 48
“The incidence for all ages is estimated at 8 to 18 cases per 100,000 person-years [2; 6; 7].”
Review of Metabolomics-Based Biomarker Research for Parkinson’s Disease
Li, X., Fan, X., Yang, H., & Liu, Y. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02657-7 · Cited by 47
CNTNAP4 deficiency in dopaminergic neurons initiates parkinsonian phenotypes
Zhang, W., Zhou, M., Lu, W., Gong, J., Gao, F., Li, Y., Xu, X., Lin, Y., Zhang, X., Ding, L., et al. (2020) · Theranostics · doi:10.7150/thno.40798 · Cited by 49
Prevalence of Parkinson’s Disease in Adults Aged 65 Years and Older in China: A Multicenter Population-Based Survey
Song, Z., Liu, S., Li, X., Zhang, M., Wang, X., Shi, Z., & Ji, Y. I. (2021) · Neuroepidemiology · doi:10.1159/000520726 · Cited by 48
Glucocorticoid receptor signaling in the brain and its involvement in cognitive function
Su, C., Huang, T., Zhang, M., Zhang, Y., Zeng, Y., & Chen, X. Y. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00355 · Cited by 52
Methylphenidate
Devos, D., Moreau, C., Delval, A., Dujardin, K., Defebvre, L., & Bordet, R. (2012) · CNS Drugs · doi:10.1007/s40263-012-0017-y · Cited by 47
Challenges and strategies of medication adherence in Parkinson's disease: A qualitative study
Shin, J. Y., Habermann, B., & Pretzer‐Aboff, I. (2015) · Geriatric Nursing · doi:10.1016/j.gerinurse.2015.01.003 · Cited by 47
Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinson’s disease in the UK and Germany
Walter, E., & Odin, P. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2014.979937 · Cited by 47
Domperidone in Parkinson’s Disease: A Perilous Arrhythmogenic or the Gold Standard?
Lertxundi, U., Domingo‐Echaburu, S., Soraluce, A., Garcia, M., Osante, B. R., & Aguirre, C. (2013) · Current Drug Safety · doi:10.2174/1574886311308010009 · Cited by 47
“As it is known, PD is clearly an age-related disease: it is rare in adults younger than 50 years and the prevalence increases with age, up to 4% in the highest age groups [56].”
Background
Newly Diagnosed Anemia Increases Risk of Parkinson’s disease: A Population-Based Cohort Study
Hong, C., Huang, Y. H., Liu, H. Y., Chiou, H., Chan, L., & Chien, L. (2016) · Scientific Reports · doi:10.1038/srep29651 · Cited by 50
REM sleep behaviour disorder: prodromal and mechanistic insights for Parkinson's disease
Tekriwal, A., Kern, D. S., Tsai, J., Ince, N. F., Wu, J., Thompson, J. A., & Abosch, A. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314471 · Cited by 48
Resolvin D1 Attenuates Mpp+-Induced Parkinson Disease via Inhibiting Inflammation in PC12 Cells
Xu, J., Gao, X., Yang, C., Chen, L., & Chen, Z. (2017) · Medical Science Monitor · doi:10.12659/msm.901995 · Cited by 47
5‐HT1F receptor‐mediated mitochondrial biogenesis for the treatment of Parkinson's disease
Scholpa, N. E., Lynn, M. K., Corum, D. G., Boger, H. A., & Schnellmann, R. G. (2017) · British Journal of Pharmacology · doi:10.1111/bph.14076 · Cited by 45
Discovering the 3′ UTR-mediated regulation of alpha-synuclein
Marchese, D., Botta-Orfila, T., Cirillo, D., Rodriguez, J. A., Livi, C. M., Fernández-Santiago, R., Ezquerra, M., Martí, M. J., Bechara, E., Tartaglia, G. G., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1048 · Cited by 45
Effect of physical activity on cognitive flexibility, depression and RBD in healthy elderly
Lerche, S., Gutfreund, A., Brockmann, K., Hobert, M. A., Wurster, I., Sünkel, U., Eschweiler, G. W., Metzger, F. G., Maetzler, W., & Berg, D. (2018) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2018.01.008 · Cited by 51
Hippocampal subfield atrophy of CA1 and subicular structures predict progression to dementia in idiopathic Parkinson’s disease
Low, A., Foo, H., Yong, T. T., Tan, L. C. S., & Kandiah, N. (2019) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-319592 · Cited by 48
Economic Evaluation of Interventions in Parkinson's Disease: A Systematic Literature Review
Afentou, N., Jarl, J., Gerdtham, U., & Saha, S. (2019) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.12755 · Cited by 48
Use of Magnetic Resonance Imaging and Artificial Intelligence in Studies of Diagnosis of Parkinson’s Disease
Xu, J., & Zhang, M. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00207 · Cited by 48
Association of Tooth Loss with New-Onset Parkinson’s Disease: A Nationwide Population-Based Cohort Study
Woo, H. G., Chang, Y., Lee, J. S., & Song, T. (2020) · Parkinson s Disease · doi:10.1155/2020/4760512 · Cited by 47
“Parkinson’s disease (PD) is an ongoing neurodegenerative disease represented by diverse progressive motor symptoms including postural instability, bradykinesia, rigidity, and tremor [1].”
Background
Effects of gold nanoparticles administration through behavioral and oxidative parameters in animal model of Parkinson’s disease
Córneo, E. D. S., Silveira, G. D. B., Scussel, R., Corrêa, M. E. A. B., Abel, J. D. S., Luiz, G. P., Feuser, P. E., Silveira, P. C. L., & Machado‐de‐Ávila, R. A. (2020) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2020.111302 · Cited by 47
A randomized single and multiple ascending dose study in healthy volunteers of LTI‐291, a centrally penetrant glucocerebrosidase activator
den Heijer, J. M., Kruithof, A. C., van Amerongen, G., de Kam, M. L., Thijssen, E., Grievink, H. W., Moerland, M., Walker, M., Been, K., Skerlj, R. T., et al. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14772 · Cited by 47
Development of bromo- and fluoro-based α, β-unsaturated ketones as highly potent MAO-B inhibitors for the treatment of Parkinson's disease
Abdelgawad, M. A., Oh, J., Parambi, D. G. T., Kumar, S., Musa, A., Ghoneim, M. M., Nayl, A. A., El-Ghorab, A. H., Ahmad, I., Patel, H., et al. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133545 · Cited by 47
Cross-sectional study discloses a positive family history for Parkinson’s disease and male gender as epidemiological risk factors for substantia nigra hyperechogenicity
Schweitzer, K., Behnke, S., Liepelt, I., Wolf, B., Grosser, C., Godau, J., Gaenslen, A., Brüssel, T., Wendt, A., Abel, F., et al. (2007) · Journal of Neural Transmission · doi:10.1007/s00702-007-0725-5 · Cited by 47
Parkinson disease: an evolutionary perspective.
Garcia-Ruiz, P. J., & Espay, A. J. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00157 · Cited by 46
Telerreabilitação vocal na doença de Parkinson
Dias, A. E., Limongi, J. C. P., Barbosa, E. R., & Hsing, W. T. (2016) · CoDAS · doi:10.1590/2317-1782/20162015161 · Cited by 49
Current Status and Future Perspectives on Stem Cell-Based Therapies for Parkinson’s Disease
Cha, Y., Park, T.-Y., Leblanc, P. R., & Kim, K. (2023) · Journal of Movement Disorders · doi:10.14802/jmd.22141 · Cited by 49
Pharmacophore model prediction, 3D-QSAR and molecular docking studies on vinyl sulfones targeting Nrf2-mediated gene transcription intended for anti-Parkinson drug design
Athar, M., Lone, M. Y., Khedkar, V. M., & Jha, P. C. (2015) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2015.1077343 · Cited by 46
Principles and Therapeutic Relevance for Targeting Mitochondria in Aging and Neurodegenerative Diseases
Serviddio, G., Romano, A. D., Cassano, T., Bellanti, F., Altomare, E., & Vendemiale, G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211796904740 · Cited by 45
“[256] de Lau LM, Breteler MM.”
Background
Where are we with surgical therapies for Parkinson's disease?
Strauss, I., Kalia, S. K., & Lozano, A. M. (2013) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(13)70044-0 · Cited by 46
“Parkinson’s Disease (PD) is one of the most common neurodegenerative diseases with an estimated prevalence of 1% in adults over the age of 60 [1].”
Background
Characterizing gait asymmetry via frequency sub-band components of the ground reaction force
Su, B.-L., Song, R., Guo, L.-Y., & Yen, C. (2014) · Biomedical Signal Processing and Control · doi:10.1016/j.bspc.2014.11.008 · Cited by 46
Epidemiological Survey-Based Formulae to Approximate Incidence and Prevalence of Neurological Disorders in the United States: a Meta-Analysis
Borlongan, C. V., Burns, J., Tajiri, N., Stahl, C. E., Weinbren, N. L., Shojo, H., Sanberg, P. R., Emerich, D. F., Kaneko, Y., & van Loveren, H. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078490 · Cited by 46
Transcription factor myocyte enhancer factor 2D regulates interleukin-10 production in microglia to protect neuronal cells from inflammation-induced death
Yang, S., Gao, L., Lu, F., Wang, B., Gao, F., Zhu, G., Cai, Z., Lai, J., & Yang, Q. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0258-z · Cited by 46
“Background Parkinson’s disease (PD) is the second most common neurodegenerative disorder and characterized pathologically by the loss of pigmented dopaminergic (DA) neurons in the substantial nigra pars compacta (SNc) [1].”
Background
Low-frequency repetitive transcranial magnetic stimulation on Parkinson motor function: a meta-analysis of randomised controlled trials
Zhu, H., Lu, Z., Jin, Y., Duan, X., Teng, J., & Duan, D.-X. (2015) · Acta Neuropsychiatrica · doi:10.1017/neu.2014.43 · Cited by 46
Relative Mortality in U.S. Medicare Beneficiaries with Parkinson Disease and Hip and Pelvic Fractures
Harris‐Hayes, M., Willis, A. W., Klein, S. E., Czuppon, S., Crowner, B. E., & Racette, B. A. (2014) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.l.01317 · Cited by 46
QSAR and Molecular Docking Techniques for the Discovery of Potent Monoamine Oxidase B Inhibitors: Computer-Aided Generation of New Rasagiline Bioisosteres
Speck‐Planche, A., & Kleandrova, V. V. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611209061734 · Cited by 46
“PD is the second most common of the NDs after AD, with an incidence between 8 and 18 per 100 000 person per year [6].”
Background
Concurrent transcranial direct current stimulation and progressive resistance training in Parkinson’s disease: study protocol for a randomised controlled trial
Hendy, A. M., Tillman, A., Rantalainen, T., Muthalib, M., Johnson, L. G., Kidgell, D. J., Wundersitz, D. W. T., Enticott, P. G., & Teo, W. (2016) · Trials · doi:10.1186/s13063-016-1461-7 · Cited by 46
VoxTester, software for digital evaluation of speech changes in Parkinson disease
Dimauro, G., Caivano, D., Bevilacqua, V., Girardi, F., & Napoletano, V. (2016) · IEEE International Symposium on Medical Measurements and Applications (MeMeA) · doi:10.1109/memea.2016.7533761 · Cited by 46
Genetic analysis of the RAB39B gene in Chinese Han patients with Parkinson's disease
Yuan, L., Deng, X., Song, Z. J., Yang, Z., Ni, B., Chen, Y., & Deng, H. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.06.019 · Cited by 46
“The prevalence of PD increases with age, from about 1% among individuals over age 65 to about 4% in those over age 85 [1].”
Background
Automatic detection of early stages of Parkinson's disease through acoustic voice analysis with mel-frequency cepstral coefficients
Jeancolas, L., Benali, H., Benkelfat, B.-E., Mangone, G., Corvol, J., Vidailhet, M., Lehéricy, S., & Petrovska‐Delacrétaz, D. (2017) · International Conference on Advanced Technologies for Signal and Image Processing · doi:10.1109/atsip.2017.8075567 · Cited by 46
“It affects 1% of people older than 60 years, and up to 4% of those over 80 [1].”
Background
Altered Functional Connectivity Between Precuneus and Motor Systems in Parkinson's Disease Patients
Thibes, R. B., Novaes, N. P., Lucato, L. T., Campanholo, K. R., Melo, L. M., Leite, C. C., Amaro, E., Barbosa, E. R., Bor‐Seng‐Shu, E., Cardoso, E. F., et al. (2017) · Brain Connectivity · doi:10.1089/brain.2017.0534 · Cited by 46
A role for viral infections in Parkinson’s etiology?
Olsen, L. K., Dowd, E., & McKernan, D. P. (2018) · Neuronal Signaling · doi:10.1042/ns20170166 · Cited by 48
Cellular and Molecular Aspects of Parkinson Treatment: Future Therapeutic Perspectives
Jamebozorgi, K., Taghizadeh, E., Rostami, D., Pormasoumi, H., Barreto, G. E., Hayat, S. M. G., & Sahebkar, A. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1419-8 · Cited by 46
“Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder that occurs in both genders and in all ethnic groups throughout the world [1, 2].”
Background
Identification of Differentially Expressed Genes and Long Noncoding RNAs Associated with Parkinson’s Disease
Chi, L.-M., Wang, L., & Jiao, D. (2019) · Parkinson s Disease · doi:10.1155/2019/6078251 · Cited by 47
“Typically, PD is documented as the second leading neurodegenerative disorder, following Alzheimer’s disease, and affects approximately 7 million people globally, most of which are elderly [2, 3].”
VPS35 D620N knockin mice recapitulate cardinal features of Parkinson’s disease
Niu, M., Zhao, F., Bondelid, K. S., Siedlak, S. L., Torres, S. L., Fujioka, H., Wang, W., Liu, J., & Zhu, X. (2021) · Aging Cell · doi:10.1111/acel.13347 · Cited by 46
Parkinson’s Disease Diagnosis in Cepstral Domain Using MFCC and Dimensionality Reduction with SVM Classifier
Rahman, A., Rizvi, S. S., Khan, A., Abbasi, A. A., Khan, S. U., & Chung, T. (2021) · Mobile Information Systems · doi:10.1155/2021/8822069 · Cited by 46
Targeting of the unfolded protein response (UPR) as therapy for Parkinson's disease
Martinez, A. N., López, N., González, C., & Hetz, C. A. (2019) · Biology of the Cell · doi:10.1111/boc.201800068 · Cited by 45
“PD is the second most common age-related disorder of the brain [de Lau and Breteler, 2006].”
Background
Dilated Perivascular Space in the Midbrain May Reflect Dopamine Neuronal Degeneration in Parkinson’s Disease
Li, Y., Zhu, Z., Chen, J., Zhang, M., Yang, Y., & Huang, P. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00161 · Cited by 47
Aging, cellular senescence and Parkinson's disease
Ma, Y., Erb, M. L., & Moore, D. J. (2025) · Journal of Parkinson s Disease · doi:10.1177/1877718x251316552 · Cited by 47
Trace elements in serum from patients with Parkinson's disease — a prospective case-control study
Gellein, K., Syversen, T. L. M., Steinnes, E., Nilsen, T. I. L., Dahl, O. P., Mitrovic, S., Duraj, D., & Flaten, T. P. (2008) · Brain Research · doi:10.1016/j.brainres.2008.05.002 · Cited by 45
Alpha-synuclein interferes with cAMP/PKA-dependent upregulation of dopamine β-hydroxylase and is associated with abnormal adaptive responses to immobilization stress
Kim, S., Park, J.-M., Moon, J., & Choi, H. J. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.11.009 · Cited by 45
Melanin affinity and its possible role in neurodegeneration
Karlsson, O., & Lindquist, N. G. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-1062-5 · Cited by 52
Risk of sleep-disordered breathing in Parkinson's disease
Chotinaiwattarakul, W., Dayalu, P., Chervin, R. D., & Albin, R. L. (2010) · Sleep And Breathing · doi:10.1007/s11325-010-0362-3 · Cited by 45
Non-motor symptoms: the core of multi-morbid Parkinson's disease
Sauerbier, A., & Chaudhuri, К. R. (2014) · British Journal of Hospital Medicine · doi:10.12968/hmed.2014.75.1.18 · Cited by 45
Genetic polymorphisms involved in dopaminergic neurotransmission and risk for Parkinson's disease in a Japanese population
Fukuoka Kinki Parkinson's Disease Study Group, Kiyohara, C., Miyake, Y., Koyanagi, M., Fujimoto, T., Shirasawa, S., Tanaka, K., Fukushima, W., Sasaki, S., Tsuboi, Y., et al. (2011) · BMC Neurology · doi:10.1186/1471-2377-11-89 · Cited by 45
SLC6A3 is a risk factor for Parkinson's disease: A meta-analysis of sixteen years’ studies
Zhai, D., Li, S.-J., Zhao, Y. Y., & Lin, Z. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2013.10.060 · Cited by 45
Occupational exposure in Parkinsonian disorders: A 43-year prospective cohort study in men
Feldman, A. L., Johansson, A. L. V., Nise, G., Gatz, M., Pedersen, N. L., & Wirdefeldt, K. (2011) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.06.009 · Cited by 45
“Risk factors for the disease are largely unknown [1].”
Background
Protective effects of berry polyphenols against age-related cognitive impairment
Bensalem, J., Dal‐Pan, A., Gillard, E., Calon, F., & Pallet, V. (2015) · Nutrition and Aging · doi:10.3233/nua-150051 · Cited by 46
“An increased risk of PD is associated with exposure to certain pesticides, insecticides and heavy metals [72–74], in contrast with a lower risk in tobacco smokers [74], coffee consumers [75] and individuals treated with anti-inflammatory drugs [74].”
Background
Multi-View Ensemble Classification of Brain Connectivity Images for Neurodegeneration Type Discrimination
Fratello, M., Caiazzo, G., Trojsi, F., Russo, A., Tedeschi, G., Tagliaferri, R., & Esposito, F. (2017) · Neuroinformatics · doi:10.1007/s12021-017-9324-2 · Cited by 46
A 3D Convolutional Neural Network Approach for the Diagnosis of Parkinson’s Disease
Martínez-Murcia, F. J., Ortíz, A., Górriz, J. M., Ramı́rez, J., Segovia, F., Salas-Gonzalez, D., Castillo-Barnés, D., & Illán, I. A. (2017) · Lecture notes in computer science · doi:10.1007/978-3-319-59740-9_32 · Cited by 45
Sleep disorders and Parkinson disease; lessons from genetics
Gan‐Or, Z., Alcalay, R. N., Rouleau, G. A., & Postuma, R. B. (2018) · Sleep Medicine Reviews · doi:10.1016/j.smrv.2018.01.006 · Cited by 47
Refolding of helical soluble α‐synuclein through transient interaction with lipid interfaces
Rovere, M., Sanderson, J. B., Fonseca‐Ornelas, L., Patel, D. S., & Bartels, T. (2018) · FEBS Letters · doi:10.1002/1873-3468.13047 · Cited by 46
Risky behaviors and Parkinson disease
Grover, S., Del, G. M. F., Kasten, M., Klein, C., Lill, C. M., & König, I. R. (2019) · Neurology · doi:10.1212/wnl.0000000000008245 · Cited by 48
Microglial Activation in the Retina of a Triple-Transgenic Alzheimer’s Disease Mouse Model (3xTg-AD)
Salobrar‐García, E., Rodrigues‐Neves, A. C., Ramirez, A. I., de Hoz, R., Fernández‐Albarral, J. A., López‐Cuenca, I., Ramirez, J. M., Ambrósio, A. F., & Salazar, J. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030816 · Cited by 45
Antioxidative role of Traditional Chinese Medicine in Parkinson's disease
Muhammad, F., Liu, Y., Zhou, Y., Yang, H., & Li, H. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114821 · Cited by 47
A systematic review of nutritional risk factors of Parkinson's disease
Ishihara, L., & Brayne, C. (2005) · Nutrition Research Reviews · doi:10.1079/nrr2005108 · Cited by 45
Dysfunction of Synaptic Vesicle Endocytosis in Parkinson’s Disease
Zou, L., Tian, Y., & Zhang, Z. (2021) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2021.619160 · Cited by 44
Linking chronic kidney disease and Parkinson’s disease: a literature review
Meléndez-Flores, J. D., & Estrada-Bellmann, I. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-020-00623-1 · Cited by 44
Resolution of Inflammation in Neurodegenerative Diseases: The Role of Resolvins
Chamani, S., Bianconi, V., Tasbandi, A., Pirro, M., Barreto, G. E., Jamialahmadi, T., & Sahebkar, A. (2020) · Mediators of Inflammation · doi:10.1155/2020/3267172 · Cited by 44
Association of Diet and Physical Activity With All-Cause Mortality Among Adults With Parkinson Disease
Zhang, X., Molsberry, S. A., Schwarzschild, M. A., Ascherio, A., & Gao, X. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.27738 · Cited by 45
Parkinson’s disease diagnosis using recurrent neural network based deep learning model by analyzing online handwriting
Kumar, K., & Ghosh, R. (2023) · Multimedia Tools and Applications · doi:10.1007/s11042-023-15811-1 · Cited by 44
Update: Protective and risk factors for Parkinson disease
Grotewold, N., & Albin, R. L. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107026 · Cited by 53
In Vitro Study of α-Synuclein Protofibrils by Cryo-EM Suggests a Cu2+-Dependent Aggregation Pathway
Zhang, H., Griggs, A. M., Rochet, J., & Stanciu, L. (2013) · Biophysical Journal · doi:10.1016/j.bpj.2013.04.050 · Cited by 45
Activated Immune Cells in Parkinson's Disease
Cao, J., Li, K., & Shen, Y. (2011) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-011-9280-9 · Cited by 44
Metacognitions, anxiety, and distress related to motor fluctuations in Parkinson's disease.
Brown, R. G., & Fernie, B. A. (2015) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2014.09.021 · Cited by 43
“The Metacognitions Questionnaire 30 (MCQ) [13] is a 30-item self-report measure that assesses five-factors pertaining to metacognition: [1] positive beliefs about worry (MCQ 1; e.”
Background

Authors: de Lau, L. M., & Breteler, M. M.
Affiliations: Erasmus MC (NL)
Corresponding author: Breteler, Monique MB
ORCID: Breteler, Monique MB
Venue: The Lancet Neurology
Publisher: Elsevier BV
Published: 2006-06
Volume: 5
Issue: 6
Pages: 525-535
ISSN: 1474-4422 (ISSN-L)
DOI: 10.1016/s1474-4422(06)70471-9
OpenAlex: W2134886133
Cited by: 4,110
References: 119
Citations by year: 2026: 108 · 2025: 172 · 2024: 229 · 2023: 230 · 2022: 307 · 2021: 315 · 2020: 337 · 2019: 290 · 2018: 301 · 2017: 284 · 2016: 259 · 2015: 288 · 2014: 232 · 2013: 200 · 2012: 159
FWCI: 7.02
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet Neurology (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: Parkinson's disease, prevalence, incidence, risk factors, prognosis, genetic susceptibility, gene-environment interaction, neurodegeneration, prospective cohort
MeSH terms: Age Factors, Humans, Parkinson Disease, Prognosis, Risk Factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Epidemiology of Parkinson's disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks